B-cell acute lymphoblastic leukemia cells (B-ALL cells)

B-cell acute lymphoblastic leukemia (B-ALL) cells represent a population of malignant, immature B-lymphocyte precursors that accumulate in the bone marrow and peripheral blood. These cells are characterized by genetic alterations that disrupt normal hematopoietic differentiation, leading to the overproduction of non-functional lymphoblasts that crowd out healthy blood cells (StatPearls, 2023). While B-ALL cells themselves are a disease state rather than a single molecular target, they express specific surface proteins such as CD19, CD20, and CD22, which serve as primary targets for modern immunotherapies including CAR-T cells and bispecific antibodies (NCI, 2024). Treatment regimens often involve a combination of intensive chemotherapy and targeted agents designed to induce apoptosis or immune-mediated clearance of the leukemic clones. Monitoring the persistence of these cells through minimal residual disease (MRD) testing is a critical clinical biomarker for predicting relapse and guiding therapeutic adjustments (PubMed, 2022).

Other names

B-cell ALLB-lineage acute lymphoblastic leukemiaPre-B acute lymphoblastic leukemiaB-lymphoblastic leukemia

Therapeutic agents targeting B-ALL cells typically act via DNA synthesis inhibition, monoclonal antibody-mediated cytotoxicity, or chimeric antigen receptor (CAR) T-cell mediated lysis of cells expressing specific surface markers like CD19 or CD22.